Biopharma Layoffs Rise in October as Six Firms Cut 50% or More
October was the first month of 2026 with more biopharma companies cutting jobs than a year earlier, BioSpace found. Six cut at least 50% of staff.

Biotech and pharma layoffs rose year over year in October for the first time in 2026, according to BioSpace tallies. Three more companies made or planned cuts than in October 2025, and the cuts affected 43% more people. Even so, the year as a whole is running far below 2025.
Six of the 15 companies with October layoffs are cutting at least 50% of their workforces, and GSK’s cuts in Belgium will affect the most people.
2026 is still well below last year
October was the first month this year in which the number of companies making or planning cuts exceeded the year before. It was the third month in which the number of affected employees rose. February showed a jump of 283% and May a jump of 47%. Besides October, only March had more companies with layoffs than the same month of 2025. Months with more affected employees were February (3,773), March (2,417) and May (6,956).
Through October, 99 companies have cut or planned to cut 19,538 people. In all of 2025, 200 biopharmas did so for 43,242 employees. BioSpace says matching last year would require at least 101 more companies to make or plan layoffs, or be newly reported as having done so, and those cuts would have to affect over 23,700 employees in November and December. Some companies disclose reductions after the fact, which can change the totals.
Six companies cut at least half their staff
Aviceda Therapeutics, based in Cambridge, Massachusetts, is winding down. Endpoints News reported that a LinkedIn post tied the decision to clinical trial results. Its asset AVD-104 missed the main goal of a Phase 2b trial last year, though the company had said in December 2025 that it planned to move the drug into Phase 3 studies.
Artiva Biotherapeutics of San Diego is laying off 94% of its workforce, the company said Oct. 27. A WARN Act notice (the federal advance-notice rule for mass layoffs) shows 131 employees leaving effective Dec. 31. Artiva is ending development of its lead candidate AlloNK after two patient deaths and questions about how long the clinical response lasted. It is also exploring options that include a merger, a sale or licensing of assets, or dissolution and liquidation.
Caribou Biosciences of Berkeley, California, is letting go of 87 people effective Dec. 7, according to its WARN notice. It had 97 employees as of Feb. 27. The company blamed a financing freeze in the CAR T field, is stopping further development of its clinical-stage pipeline and is considering strategic alternatives such as a merger or acquisition.
LENZ Therapeutics of Solana Beach, California, will cut about 75% of its workforce and keep around 40 full-time employees, an SEC filing shows. President and CEO Eef Schimmelpennink leaves Dec. 1. LENZ sells Vizz, an eye drop for presbyopia, and said the reorganization puts consumer marketing first. It announced the change alongside third quarter earnings that fell short of expectations.
Enlivex, based in Nes Ziona, Israel, is cutting about 60% of its staff, it announced Oct. 19. It had 34 full-time employees as of Dec. 31, 2025. The money saved goes toward Allocetra, a cell therapy for knee osteoarthritis. CEO Oren Hershkovitz is taking a 40% pay cut and the management team 20%.
EyePoint of Watertown, Massachusetts, is cutting 53% of its team, it announced Oct. 19. A WARN notice covers 105 employees at its Watertown headquarters and Northbridge manufacturing site, with effective dates from Dec. 31, 2026, to Jan. 31, 2027. The move follows a disappointing result for duravyu in wet age-related macular degeneration. EyePoint is ending those trials early and will focus on a late-stage program in diabetic macular edema.
Why it matters: GSK affects the most workers
GSK is eliminating more than 1,200 roles in Belgium, as many as 1,217, according to the numbers reported. L’Echo reported that the Rixensart, Wavre and Gembloux sites are affected. A company spokesperson told BioSpace the cuts belong to a three-year, $2.5 billion global restructuring that shifts money toward the late-stage pipeline and research and development.
How BioSpace counts
The tally leaves out contract development and manufacturing organizations, contract research organizations, tools and services businesses and medical device firms. Affected-employee numbers come from company officials, press releases, WARN notices, SEC filings and media reports. Some companies share only a percentage of staff affected, so several figures are estimates.
Source: BioSpace



